Skip to content

 Activity Post Test and Evaluation Form

Post Test

Please note that to receive credit you must achieve a score of at least 80%.

Pharmacists: The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/.
1.The most common route of opioid abuse is:(Required.)
2.Which of the following is an immediate-release opioid with abuse-deterrent technology?(Required.)
3.Current abuse-deterrent technologies cannot prevent:(Required.)
4.An opioid antagonist that is used in abuse-deterrent formulations is:(Required.)
5.Ideally, patients receiving opioid medications should be counseled about OIC risk and prevention:(Required.)
6.Opioid effects on the gastrointestinal system include all of the following except:(Required.)
7.Which of the following is not a peripherally-acting mu-opioid receptor antagonist (PAMORA)?(Required.)
8.A 67-year-old man who is receiving oxycodone for low back pain complains of severe constipation for the past 2 weeks consisting of straining, excessive time on the toilet, and a feeling of incomplete bowel emptying. He has tried OTC laxatives with inadequate response. He says that sometimes he has to take an extra dose of oxycodone to manage pain. An appropriate next step for this patient is:(Required.)